Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28225505 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL27094 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL27707116 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL15740526 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL14260907 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL18387973 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL24998924 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL29107067 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| SCHEMBL15740500 | 1.00 | HRH3 (0.38) | HRH3OPRM1L3MBTL1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL31094680 | 0.98 | L3MBTL1 (0.40) | HRH3OPRM1L3MBTL1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115291-A1 | POLYSILOXANE COMPOSITION | MERCK PATENT GMBH (DE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024115571-A1 | POLYSILOXANE COMPOSITION | MERCK PATENT GMBH (DE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4352163-A1 | POLYSILOXANE COMPOSITION | Merck Patent GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024002921-A1 | POLYSILOXANE COMPOSITION | MERCK PATENT GMBH (DE) | 2024-01-04 | — | — | WO | disclosed |
| CN-117043136-A | Fluorine-based ionic liquid and method for producing same | 第一工业制药株式会社 | 2023-11-10 | — | — | CN | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022258425-A1 | POLYSILOXANE COMPOSITION | MERCK PATENT GMBH (DE) | 2022-12-15 | — | — | WO | disclosed |
| EP-3782212-A1 | ADDITIVE MANUFACTURING USING ELECTROCHEMICALLY ACTIVE FORMULATIONS | Ramot at Tel-Aviv University Ltd. (IL) | 2021-02-24 | — | — | EP | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-109628004-A | Film, surface protective film and optical component with finishing coat | 日东电工株式会社 | 2019-04-16 | — | — | CN | disclosed |
| CN-104620437-B | Sodium rechargeable battery | 住友电气工业株式会社 | 2017-11-24 | — | — | CN | disclosed |
| US-7605271-B2 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20060223995-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1707265-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HRH3 1000/4885OPRM1 3497/4885L3MBTL1 2011/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HRH3 994/4885OPRM1 607/4885L3MBTL1 4285/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HRH3 1000/4885OPRM1 3497/4885L3MBTL1 2011/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | HRH3 994/4885OPRM1 607/4885L3MBTL1 4285/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HRH3 1000/4885OPRM1 3497/4885L3MBTL1 2011/4885 |
| US-20060223995-A1 | Superhigh purity ionic liquid | SLC7A5, SLC7A1, SLC43A1 | HRH3 709/4885OPRM1 3202/4885L3MBTL1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.